|
The Cancer Epigenome research laboratory is focusing on
integrated epigenomic and genomic profiling in Asian cancers
using enabling technologies such as ChIP-Seq, RNA-seq,
Whole-genome and DNA methylation sequencing. The data is then
correlated with clinicopathological information including how
patients respond to certain drugs. Our research goals are to:
- understand the molecular mechanism underlying these
cancers;
- to identify novel biomarkers than can help determine
the nature and behaviour of the disease as well as predicting
patients' response to certain drugs; and
- to identify novel therapeutic targets with a focus on
chromatin enzymes.
The group has hosted and trained clinician scientists, both
locally and abroad, who are interested in pursuing
translational research. To date, the laboratory has been
instrumental in establishing and nurturing several cancer
type-based translational research programs at the National
Cancer Centre Singapore including biliary tract cancer,
lymphoma, sarcoma, breast disease, urological cancer, and
peritoneal cancer. The group always emphasizes on collaboration
(both local and international) which is key to scientific
breakthroughs. The group is now part of the Singapore team that
is leading the International Cancer Genome Consortium (ICGC)
project on biliary tract cancer. The group is also an integral
part of the Lymphoma TCR (Translational Clinical Research)
Program.
|
Professor Bin Tean TEH
Director, SingHealth Duke-NUS Institute of Biodiversity Medicine (BD-MED)
Deputy Chief Executive Officer (Research), National Cancer Centre Singapore
Deputy Director (Global Relations), SingHealth Duke-NUS
Institute of Precision Medicine
Professor, Duke-NUS
Medical School, Singapore
Senior Principal Investigator,
Institute of Molecular and Cell Biology, Singapore
Senior Group Leader, Genome Institute of Singapore
|
